Mi-Jin Kim , Bong Hyun Sung , Hyun-Joo Park , Jung-Hoon Sohn , Jung-Hoon Bae
{"title":"酵母在GAL启动子下无诱导剂强表达的新平台宿主","authors":"Mi-Jin Kim , Bong Hyun Sung , Hyun-Joo Park , Jung-Hoon Sohn , Jung-Hoon Bae","doi":"10.1016/j.btre.2022.e00763","DOIUrl":null,"url":null,"abstract":"<div><p>The <em>gal80</em> mutant of yeast <em>Saccharomyces cerevisiae</em> is used for the constitutive expression under strong <em>GAL</em> promoters without galactose induction. To enhance productivity of <em>gal80</em> mutant, an alternative strain, allgal, was developed by removing all galactose-utilizing genes that consume significant cellular resources in the <em>gal80</em> strain when cultured in non-galactose conditions. The efficacy of the allgal mutant (<em>gal80, gal1, gal2, gal7</em>, and <em>gal10</em>) was verified by assessing the secretory expression of three recombinant proteins, <em>Candida antarctica</em> lipase B (CalB), human serum albumin (HSA), and human epidermal growth factor (hEGF), using the <em>GAL10</em> promoter. The growth of the allgal mutant was enhanced by 15–38% compared to the <em>gal80</em> mutant, and the secretion of recombinant proteins also increased by 16–22% in fed-batch fermentation. Thus, the expression of recombinant proteins using <em>GAL10</em> promoter in the allgal mutant is suitable for the economical production of recombinant proteins in <em>S. cerevisiae</em>.</p></div>","PeriodicalId":38117,"journal":{"name":"Biotechnology Reports","volume":"36 ","pages":"Article e00763"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/82/main.PMC9493058.pdf","citationCount":"2","resultStr":"{\"title\":\"A new platform host for strong expression under GAL promoters without inducer in Saccharomyces cerevisiae\",\"authors\":\"Mi-Jin Kim , Bong Hyun Sung , Hyun-Joo Park , Jung-Hoon Sohn , Jung-Hoon Bae\",\"doi\":\"10.1016/j.btre.2022.e00763\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The <em>gal80</em> mutant of yeast <em>Saccharomyces cerevisiae</em> is used for the constitutive expression under strong <em>GAL</em> promoters without galactose induction. To enhance productivity of <em>gal80</em> mutant, an alternative strain, allgal, was developed by removing all galactose-utilizing genes that consume significant cellular resources in the <em>gal80</em> strain when cultured in non-galactose conditions. The efficacy of the allgal mutant (<em>gal80, gal1, gal2, gal7</em>, and <em>gal10</em>) was verified by assessing the secretory expression of three recombinant proteins, <em>Candida antarctica</em> lipase B (CalB), human serum albumin (HSA), and human epidermal growth factor (hEGF), using the <em>GAL10</em> promoter. The growth of the allgal mutant was enhanced by 15–38% compared to the <em>gal80</em> mutant, and the secretion of recombinant proteins also increased by 16–22% in fed-batch fermentation. Thus, the expression of recombinant proteins using <em>GAL10</em> promoter in the allgal mutant is suitable for the economical production of recombinant proteins in <em>S. cerevisiae</em>.</p></div>\",\"PeriodicalId\":38117,\"journal\":{\"name\":\"Biotechnology Reports\",\"volume\":\"36 \",\"pages\":\"Article e00763\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/82/main.PMC9493058.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2215017X22000613\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215017X22000613","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
A new platform host for strong expression under GAL promoters without inducer in Saccharomyces cerevisiae
The gal80 mutant of yeast Saccharomyces cerevisiae is used for the constitutive expression under strong GAL promoters without galactose induction. To enhance productivity of gal80 mutant, an alternative strain, allgal, was developed by removing all galactose-utilizing genes that consume significant cellular resources in the gal80 strain when cultured in non-galactose conditions. The efficacy of the allgal mutant (gal80, gal1, gal2, gal7, and gal10) was verified by assessing the secretory expression of three recombinant proteins, Candida antarctica lipase B (CalB), human serum albumin (HSA), and human epidermal growth factor (hEGF), using the GAL10 promoter. The growth of the allgal mutant was enhanced by 15–38% compared to the gal80 mutant, and the secretion of recombinant proteins also increased by 16–22% in fed-batch fermentation. Thus, the expression of recombinant proteins using GAL10 promoter in the allgal mutant is suitable for the economical production of recombinant proteins in S. cerevisiae.
Biotechnology ReportsImmunology and Microbiology-Applied Microbiology and Biotechnology
CiteScore
15.80
自引率
0.00%
发文量
79
审稿时长
55 days
期刊介绍:
Biotechnology Reports covers all aspects of Biotechnology particularly those reports that are useful and informative and that will be of value to other researchers in related fields. Biotechnology Reports loves ground breaking science, but will also accept good science that can be of use to the biotechnology community. The journal maintains a high quality peer review where submissions are considered on the basis of scientific validity and technical quality. Acceptable paper types are research articles (short or full communications), methods, mini-reviews, and commentaries in the following areas: Healthcare and pharmaceutical biotechnology Agricultural and food biotechnology Environmental biotechnology Molecular biology, cell and tissue engineering and synthetic biology Industrial biotechnology, biofuels and bioenergy Nanobiotechnology Bioinformatics & systems biology New processes and products in biotechnology, bioprocess engineering.